Medizinische Universität Graz - Research portal
Navigation/Search
- Researchers
- Institutions
- Projects
- Publications
- Partners
- Sponsors
- Equipment
- Knowhow
- Fields of Research
"Faces" of the day:
Selected Publication:
SHR Neuro Cancer Cardio Lipid Metab Microb
Schuller, M; Oberhuber, M; Prietl, B; Zügner, E; Prugger, EM; Magnes, C; Kirsch, AH; Schmaldienst, S; Pieber, T; Brodmann, M; Rosenkranz, AR; Eller, P; Eller, K.
Alterations in the Kynurenine-Tryptophan Pathway and Lipid Dysregulation Are Preserved Features of COVID-19 in Hemodialysis.
Int J Mol Sci. 2022; 23(22):
Doi: 10.3390/ijms232214089
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
- Leading authors Med Uni Graz
- Eller Kathrin
- Schuller Max
- Co-authors Med Uni Graz
- Brodmann Marianne
- Eller Philipp
- Kirsch Alexander
- Pieber Thomas
- Prietl Barbara
- Rosenkranz Alexander
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- Coronavirus disease 2019 (COVID-19)-induced metabolic alterations have been proposed as a source for prognostic biomarkers and may harbor potential for therapeutic exploitation. However, the metabolic impact of COVID-19 in hemodialysis (HD), a setting of profound a priori alterations, remains unstudied. To evaluate potential COVID-19 biomarkers in end-stage kidney disease (CKD G5), we analyzed the plasma metabolites in different COVID-19 stages in patients with or without HD. We recruited 18 and 9 asymptomatic and mild, 11 and 11 moderate, 2 and 13 severely affected, and 10 and 6 uninfected HD and non-HD patients, respectively. Plasma samples were taken at the time of diagnosis and/or upon admission to the hospital and analyzed by targeted metabolomics and cytokine/chemokine profiling. Targeted metabolomics confirmed stage-dependent alterations of the metabolome in non-HD patients with COVID-19, which were less pronounced in HD patients. Elevated kynurenine levels and lipid dysregulation, shown by an increase in circulating free fatty acids and a decrease in lysophospholipids, could distinguish patients with moderate COVID-19 from non-infected individuals in both groups. Kynurenine and lipid alterations were also associated with ICAM-1 and IL-15 levels in HD and non-HD patients. Our findings support the kynurenine pathway and plasma lipids as universal biomarkers of moderate and severe COVID-19 independent of kidney function.
- Find related publications in this database (using NLM MeSH Indexing)
- Humans - administration & dosage
- Kynurenine - administration & dosage
- Tryptophan - administration & dosage
- COVID-19 - administration & dosage
- Renal Dialysis - administration & dosage
- Lipids - administration & dosage
- Find related publications in this database (Keywords)
- COVID-19
- metabolomics
- hemodialysis patients
- kynurenine
- lipid dysregulation